3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
2
Unknown
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Endometrial Neoplasms
2
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Endometriosis
1
Carcinoma, Endometrioid
1
Adenomyosis
1
Interventions
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Carboplatin
6
Specimen Handling
5
Paclitaxel
5
Brachytherapy
5
Fluorodeoxyglucose F18
4
dostarlimab
3
atezolizumab
3
Trastuzumab
3
Radiation
3
Platinum
3
Nivolumab
3
Human Papillomavirus DNA Tests
3
Docetaxel
3
Colposcopy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tislelizumab
2
spartalizumab
2
olaparib
2
human papillomavirus vaccine, L1 type 16, 18
2
durvalumab
2
Vaccines
2
Surveys and Questionnaires
2
Standard of Care
2
Robotic Surgical Procedures
2
Radiotherapy, Intensity-Modulated
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Uterine Cervical Neoplasms
×
Hysterectomy
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled